Immunoenhancement with combined rabies and aluminium-adjuvanted tetanus vaccines. 1989

P Phanuphak, and P Khaoplod, and B Sriwanthana, and T Phanpanich, and S Wongurai, and M Roumiantzeff
Science Division, Thai Red Cross Society, Bangkok, Thailand.

The effect of combining tetanus toxoid in the same syringe with purified Vero cell rabies vaccine (PVRV) was investigated in the 2-1-1 regimen of PVRV. The 2-1-1 regimen alone was as immunogenic as the five-dose regimen, while saving one dose of vaccine and two clinic visits. When aluminium hydroxide-adsorbed tetanus toxoid was used to dissolve PVRV on days 0 (one of the two doses) and 21, the anti-rabies antibody was significantly increased. Aluminium-free tetanus toxoid was ineffective, suggesting that immunoenhancement was due to aluminium adjuvant. In addition, anti-tetanus antibody was unaffected and the side-effects were not increased by such mixing.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011818 Rabies Acute VIRAL CNS INFECTION affecting mammals, including humans. It is caused by RABIES VIRUS and usually spread by contamination with virus-laden saliva of bites inflicted by rabid animals. Important animal vectors include the dog, cat, bat, fox, raccoon, skunk, and wolf. Encephalitic Rabies,Furious Rabies,Hydrophobia,Paralytic Rabies,Lyssa,Furious Raby,Lyssas,Rabies, Encephalitic,Rabies, Furious,Raby, Furious
D011819 Rabies Vaccines Vaccines or candidate vaccines used to prevent and treat RABIES. The inactivated virus vaccine is used for preexposure immunization to persons at high risk of exposure, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis. Rabies Human Diploid Cell Vaccine,Rabies Vaccine,Vaccine, Rabies,Vaccines, Rabies
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

P Phanuphak, and P Khaoplod, and B Sriwanthana, and T Phanpanich, and S Wongurai, and M Roumiantzeff
November 1999, Vaccine,
P Phanuphak, and P Khaoplod, and B Sriwanthana, and T Phanpanich, and S Wongurai, and M Roumiantzeff
April 1992, Pharmacology & toxicology,
P Phanuphak, and P Khaoplod, and B Sriwanthana, and T Phanpanich, and S Wongurai, and M Roumiantzeff
January 1986, Developments in biological standardization,
P Phanuphak, and P Khaoplod, and B Sriwanthana, and T Phanpanich, and S Wongurai, and M Roumiantzeff
January 2015, Przeglad epidemiologiczny,
P Phanuphak, and P Khaoplod, and B Sriwanthana, and T Phanpanich, and S Wongurai, and M Roumiantzeff
March 1969, British medical journal,
P Phanuphak, and P Khaoplod, and B Sriwanthana, and T Phanpanich, and S Wongurai, and M Roumiantzeff
July 1982, Journal of biological standardization,
P Phanuphak, and P Khaoplod, and B Sriwanthana, and T Phanpanich, and S Wongurai, and M Roumiantzeff
October 2019, Archives of toxicology,
P Phanuphak, and P Khaoplod, and B Sriwanthana, and T Phanpanich, and S Wongurai, and M Roumiantzeff
November 1997, Zentralblatt fur Bakteriologie : international journal of medical microbiology,
P Phanuphak, and P Khaoplod, and B Sriwanthana, and T Phanpanich, and S Wongurai, and M Roumiantzeff
October 1995, Vaccine,
P Phanuphak, and P Khaoplod, and B Sriwanthana, and T Phanpanich, and S Wongurai, and M Roumiantzeff
November 2009, Vaccine,
Copied contents to your clipboard!